CompletedPhase 1NCT02684383

Evaluation of the Safety and Immunogenicity of rDEN3Δ30, a Live Attenuated Monovalent Dengue Virus Vaccine

Studying Dengue fever

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigator: Kristen Pierce, MD, MD
University of Vermont
Intervention: rDEN3∆30(biological)
Enrollment: 14 enrolled
Eligibility: 18-50 years · All sexes
Timeline: 2016

Study locations (2)

Center for Immunization Research (CIR), Johns Hopkins School of Public Health, Baltimore, Maryland, United States
University of Vermont Medical Center, Burlington, Vermont, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02684383 on ClinicalTrials.gov

Other trials for Dengue fever

Additional recruiting or active studies for the same condition.

See all trials for Dengue fever →

← Back to all trials